JAK3 and rheumatoid arthritis: The critical role of JAK/STAT pathway activation in RA was further confirmed by the US Food and Drug Administration (FDA) approval of the JAK3 selective small molecule inhibitor (SMI), tofacitinib, for the pharmacological treatment of RA (Ciobanu et al., 2020).